首页> 外文期刊>Archives of disease in childhood >Height and weight pattern up to 20 years after treatment for acute lymphoblastic leukaemia (see comments)
【24h】

Height and weight pattern up to 20 years after treatment for acute lymphoblastic leukaemia (see comments)

机译:急性淋巴细胞白血病治疗后长达20年的身高和体重模式(请参阅评论)

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To assess height and body mass index standard deviation scores up to 20 years after treatment for acute lymphoblastic leukaemia (ALL). SUBJECTS AND METHODS: Height and body mass index standard deviation scores were measured in 33 patients (14 boys and 19 girls) with childhood ALL at diagnosis, after the end of treatment, at final height, and at follow up 10-20 years (median, 16.2) after diagnosis. Eleven patients were treated with chemotherapy only and 22 patients were treated with chemotherapy and cranial irradiation. RESULTS: In the chemotherapy only group, height standard deviation scores were the same at follow up as at diagnosis, but there was a significant decrease in height standard deviation scores during treatment. Mean body mass index standard deviation scores increased steadily from the start of treatment until final height and continued to increase from final height until follow up. In the cranially irradiated group, mean height standard deviation scores decreased steadily from the start of treatment until follow up. Mean body mass index standard deviation scores increased continuously from the start of treatment until final height and from final height until follow up. CONCLUSION: Chemotherapy combined with cranial irradiation and chemotherapy alone might be persisting risk factors for obesity even after final/height has been attained in patients treated for childhood ALL. Chemotherapy is a risk factor for reduced final height only when administered in combination with cranial irradiation. These problems need to be recognised and dealt with at follow up examination.
机译:目的:评估急性淋巴细胞白血病(ALL)治疗后长达20年的身高和体重指数标准差评分。研究对象和方法:在诊断,治疗结束后,最终身高和随访10-20年(中位数)的33例儿童ALL患者中测量了身高和体重指数标准差评分。 ,16.2)诊断后。仅11例接受化学疗法治疗,22例接受化学疗法和颅骨放射治疗。结果:在仅化疗组,随访时的身高标准偏差评分与诊断时相同,但治疗期间身高标准偏差评分显着降低。从治疗开始到最终身高,平均体重指数标准差评分稳步上升,而从随访身高开始直至随访均持续增加。在颅骨照射组中,从治疗开始到随访,平均身高标准偏差评分稳步下降。从治疗开始至最终身高,平均体重指数标准差评分不断提高,从治疗后直至随访,其平均身高指数均持续升高。结论:化学疗法联合颅骨放疗和单纯化疗可能是肥胖的持续危险因素,即使在治疗儿童ALL的患者达到最终/身高后也是如此。仅当与颅骨照射联合使用时,化学疗法才是降低最终身高的危险因素。这些问题需要在后续检查中予以认识和处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号